The SARS Coronavirus Clone and Reagent Core serve and interact with and are integral to the smooth function of each of the projects and cores of the proposal.
Aim 1 is to provide a standardized source of SARS-CoV cDNA clones, plasmids, recombinant SARS-CoV proteins, diagnostic reagents, antibodies, platform vaccine candidates (e.g., VRPs, NDV vaccine platforms), molecularly cloned viruses and various SARS-CoV wild type viruses. A centralized source of these reagents is absolutely essential for identifying pathogenic determinants and making valid comparisons among the various SARS vaccine candidates generated during the course of the Program. In this capacity, the Core will continue to produce reagents necessary for successful progression of Projects 1-4 and the animal models core.
Aim 2 is to produce molecularly cloned SARS viruses that contain heterologous and ancestral S glycoprotein's (vS), ORF3a (vX3) and ORF6 (vX6) IFN antagonist genes and ORF8 (v8) derived by in vitro reconstruction of published sequences from mainland China and from exotic animal origins. These SARS-CoV-vS isolates will provide us an opportunity to 1) measure and compare cross neutralization titers among the various vaccine candidates, 2) determine if evolution in IFN antagonist genes was associated with increased activity in human cells, 3) examine the role of variant S and IFN antagonist genes in SARS-CoV pathogenesis.
Aim 3 is to consult with Projects 1 and 2 and assemble chimeric candidate live virus vaccines that contain multiple attenuating alleles layered throughout the SARS genome. The goal is to create live attenuated SARS virus vaccines that are extremely safe and will defy RNA recombination with circulating coronaviruses in nature. Select candidate live attenuated vaccines with be chemically inactivated.
In aim 4, the Core will sequence select molecularly cloned SARS-CoV isolates, revertant and recombinant viruses generated from Projects 1-4 research design. The Core will assist in the identification and confirmation of 2nd site compensatory mutations that enhance in vitro growth with passage.
In Aim 5, the Core prepares and maintains candidate VRP and ARRP vaccine strains for use in the various projects.
In Aim 6, the Core engages various projects and cores to obtain and produce novel reagents, and to distribute them in quantity and assist in maintaining secure inventories of SARS-CoV reagents and viruses.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Chapel Hill
United States
Zip Code
Gonzalez, P N; Pavlicev, M; Mitteroecker, P et al. (2016) Genetic structure of phenotypic robustness in the collaborative cross mouse diallel panel. J Evol Biol 29:1737-51
Sheahan, Timothy; Whitmore, Alan; Long, Kristin et al. (2011) Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus. J Virol 85:217-30
Eckerle, Lance D; Becker, Michelle M; Halpin, Rebecca A et al. (2010) Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing. PLoS Pathog 6:e1000896
Brooke, Christopher B; Deming, Damon J; Whitmore, Alan C et al. (2010) T cells facilitate recovery from Venezuelan equine encephalitis virus-induced encephalomyelitis in the absence of antibody. J Virol 84:4556-68
Li, Kelvin; Venter, Eli; Yooseph, Shibu et al. (2010) ANDES: Statistical tools for the ANalyses of DEep Sequencing. BMC Res Notes 3:199
Rockx, Barry; Donaldson, Eric; Frieman, Matthew et al. (2010) Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus. J Infect Dis 201:946-55
Frieman, Matthew B; Chen, Jun; Morrison, Thomas E et al. (2010) SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism. PLoS Pathog 6:e1000849
Zornetzer, Gregory A; Frieman, Matthew B; Rosenzweig, Elizabeth et al. (2010) Transcriptomic analysis reveals a mechanism for a prefibrotic phenotype in STAT1 knockout mice during severe acute respiratory syndrome coronavirus infection. J Virol 84:11297-309
Frieman, Matthew; Ratia, Kiira; Johnston, Robert E et al. (2009) Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J Virol 83:6689-705
Rockx, Barry; Baas, Tracey; Zornetzer, Gregory A et al. (2009) Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection. J Virol 83:7062-74

Showing the most recent 10 out of 37 publications